Predictors of Internal Mammary Artery Graft Failure

The Internal Mammary Artery (IMA) is the preferred conduit for bypassing the left anterior descending artery (LAD) in patients undergoing coronary artery bypass grafting. There is no systematic evaluation of the frequency and predictors of IMA failure or long-term outcomes.

 

The PREVENT IV included 1539 patients receiving IMA-LAD revascularization with 12 and 18 month follow up. Logistic regression was used to identify characteristics associated with IMA failure (≥75% stenosis) and itsconnectionwith clinical events such as death, myocardial infarction, and repeat revascularization.

 

IMA failure occurred in 132 patients (8.6%). Predictors of IMA graft failure were LAD stenosis <75% (OR 1.76; CI 95% 1.19-2.59), additional bypass graft to diagonal branch (OR 1.92; CI 95% 1.33-2.76), and not having diabetes (OR 1.82; CI 95% 1.20-2.78).

 

IMA failure was associated with a higher incidence of AMI mostly due to a higher rate of repeat revascularization.

 

Conclusion
IMA failure is associated to clinical events and is observed mainly in patients with a prior intermediate LAD stenosis or with an additional bypass graft to a diagonal branch. This finding should be taken into account when indication surgery for patients with no functional evidence of ischemia in LAD territory.

 

Original Title: Frequency and Predictors of Internal Mammary Artery Graft Failure and Subsequent Clinical Outcomes: Insights From the PREVENT IV Trial. Reference: Ralf E. Harskamp et al. Circulation. 2015 Dec 8.Epub ahead of print.


Suscríbase a nuestro newsletter semanal

Reciba resúmenes con los últimos artículos científicos

Su opinión nos interesa. Puede dejar su comentario, reflexión, pregunta o lo que desee aquí abajo. Será más que bienvenido.

More articles by this author

ACC 2026 | IVUS-CHIP Trial: Intravascular ultrasound–guided versus angiography-guided complex PCI

Optimization of percutaneous coronary intervention (PCI) in complex lesions remains a relevant clinical challenge. In this context, the IVUS-CHIP trial was designed to evaluate...

ACC 2026 | ALL-RISE Trial: Coronary Physiological Assessment Using FFRangio

Coronary physiological assessment using pressure-wire techniques (FFR/iFR) carries a Class IA recommendation in ACC/AHA guidelines; however, its use remains limited due to factors such...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...

ACC 2026 | CHIP-BCIS3: Impella use as support in high-risk complex PCI

The use of percutaneous ventricular support during high-risk complex PCI has been proposed as a strategy to prevent hemodynamic deterioration in patients with severe...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | Extended follow-up of the TRI-FR study: Edge-to-edge percutaneous repair in isolated severe tricuspid regurgitation

Severe tricuspid regurgitation (TR) is associated with chronic systemic venous congestion, recurrent hospitalizations for heart failure (HF), and a significant deterioration in quality of...

ACC 2026 | SirPAD Trial: Sirolimus-coated balloon angioplasty in infrainguinal arterial disease

Paclitaxel-coated balloons have demonstrated improved patency in peripheral arterial disease (PAD), although questions remain regarding safety and applicability across different vascular territories. In this...

ACC 2026 | IVUS-CHIP Trial: Intravascular ultrasound–guided versus angiography-guided complex PCI

Optimization of percutaneous coronary intervention (PCI) in complex lesions remains a relevant clinical challenge. In this context, the IVUS-CHIP trial was designed to evaluate...